Hematologic CancerHYCVANCT05942885
Hypnosis: a Path to Appeasement
A study testing anxiety questionnaire in people with Hematologic Cancer, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
Hypnosis is a technique allowing the patient to focus his mental attention on a thought or a sensation, with the aim of reducing or modulating the intensity of a negative feeling or an ordeal encountered during the course of treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematologic Cancer
- What is being tested?
- anxiety questionnaire
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- 30 Oct 2023to 30 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients over 18 years old, fluent in French.
- Patients starting hypnotherapy for anxiety disorders.
- Anxiety score on the HADS scale (Hospital Anxiety and Depression Scale) greater than or equal to 8/21
- Patients with diffuse large cell B-cell lymphoma or follicular lymphoma, whatever the stage of the disease.
- Diagnosis announcement less than 2 months old
Who cannot join
- Persons deprived of their liberty by a judicial or administrative decision
- Adults subject to a legal protection measure
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service MB1 - Hôpital Lyon Sud - HCL
Lyon, Pierre-Bénite, 69495
Thomas Bert, 04.78.86.43.45, thomas.bert01@chu-lyon.fr
About this study
Hypnosis is a technique allowing the patient to focus his mental attention on a thought or a sensation, with the aim of reducing or modulating the intensity of a negative feeling or an ordeal encountered during the course of treatment. This tool can be used when patients are faced with chronic disorders (pain, anxiety, ...) or iatrogenic effects (nausea, asthenia, ...).
The patient is referred to hypnosis care by the doctor, psychologist or paramedics who follow him, when they detect a need.
Several scientific studies have shown the effectiveness of hypnosis in improving the quality of life of patients with breast cancer and in reducing pain during invasive procedures. On the other hand, in hematology, no research has measured the evolution of anxiety, over time, in patients receiving hypnotherapy.
- Conditions
- Hematologic Cancer
- Being tested
- anxiety questionnaire
- Keywords
- hypnosis, Diffuse large cell B-cell lymphoma, follicular lymphoma, anxiety
- Medical subject headings
- Hematologic Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
anxiety questionnaireOther
Patient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session
| Study group | Role | What they receive |
|---|---|---|
| Anxiety scores | Experimental | Not described Receives: Other: anxiety questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evolution of anxiety
Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Measured: Week 6 after 2 hypnosis sessions
Secondary outcomes (7)
Evolution of anxiety before hypnotherapy and after 3 months of follow-up in hypnotherapy
Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Measured: Month 3 after 3 hypnosis sessions
Evolution of anxiety between D0 and M3 according to the type of lymphoma
Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : follicular lymphoma and diffuse large b-cell lymphoma. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Measured: Month 3 after 3 hypnosis sessions
Evolution of anxiety between D0 and W6 according to the type of lymphoma
Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : follicular lymphoma and diffuse large b-cell lymphoma. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Measured: Week 6 after 2 hypnosis sessions
Evolution of anxiety between D0 and W6 according to the gender of the patient
Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : man and woman. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Measured: Week 6 after 2 hypnosis sessions
Evolution of anxiety between D0 and M3 according to the gender of the patient
Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : man and woman. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Measured: Month 3 after 3 hypnosis sessions
Evolution of anxiety between D0 and W6 according to age category
Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions for two subgroups : under 60 years old ans over 60 years old. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Measured: Week 6 after 2 hypnosis sessions
Evolution of anxiety between D0 and M3 according to age category
Difference in anxiety measured before starting hypnotherapy care and after 3 hypnosis sessions for two subgroups : under 60 years old ans over 60 years old. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
Measured: Month 3 after 3 hypnosis sessions
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2023
- Study start30 Oct 2023
- Primary completion30 Apr 2026 (estimated)
- Study completion30 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematologic CancerStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Thomas BERT, Principal investigator, Hospices Civils de Lyon
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05942885
- Sponsor's protocol ID
- 69HCL23_0336
- Acronym
- HYCVA
- Status last verified
- Sep 2025
- First submitted
- 3 Jul 2023
- Last updated
- 11 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hypnosis: a Path to Appeasement
- ClinicalTrials.gov ID
- NCT05942885
- Acronym / sponsor ID
- HYCVA / 69HCL23_0336
- Conditions
- Hematologic Cancer
- Keywords
- hypnosis, Diffuse large cell B-cell lymphoma, follicular lymphoma, anxiety
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 30 Oct 2023 (actual)
- Primary completion
- 30 Apr 2026 (estimated)
- Study completion
- 30 Jul 2026 (estimated)
- First posted
- 12 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hypnosis is a technique allowing the patient to focus his mental attention on a thought or a sensation, with the aim of reducing or modulating the intensity of a negative feeling or an ordeal encountered during the course of treatment. This tool can be used when patients are faced with chronic disorders (pain, anxiety, ...) or iatrogenic effects (nausea, asthenia, ...).
The patient is referred to hypnosis care by the doctor, psychologist or paramedics who follow him, when they detect a need.
Several scientific studies have shown the effectiveness of hypnosis in improving the quality of life of patients with breast cancer and in reducing pain during invasive procedures. On the other hand, in hematology, no research has measured the evolution of anxiety, over time, in patients receiving hypnotherapy.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Anxiety scores | Experimental | Other: anxiety questionnaire |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients over 18 years old, fluent in French.
- Patients starting hypnotherapy for anxiety disorders.
- Anxiety score on the HADS scale (Hospital Anxiety and Depression Scale) greater than or equal to 8/21
- Patients with diffuse large cell B-cell lymphoma or follicular lymphoma, whatever the stage of the disease.
- Diagnosis announcement less than 2 months old
Key exclusion criteria (2 listed)
- Persons deprived of their liberty by a judicial or administrative decision
- Adults subject to a legal protection measure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| anxiety questionnairePatient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session | Other | Anxiety scores |
Primary outcome
Evolution of anxiety
Time frame: Week 6 after 2 hypnosis sessions
Difference in anxiety measured before starting hypnotherapy care and after 2 hypnosis sessions. It will be measured by the Hospital Anxiety and Depression Scale. This scale gives a score according to the level of anxiety ranging from 0 to 21. The higher the score, the more the patient is anxious.
7 secondary outcomes
Evolution of anxiety before hypnotherapy and after 3 months of follow-up in hypnotherapy
Time frame: Month 3 after 3 hypnosis sessions
Evolution of anxiety between D0 and M3 according to the type of lymphoma
Time frame: Month 3 after 3 hypnosis sessions
Evolution of anxiety between D0 and W6 according to the type of lymphoma
Time frame: Week 6 after 2 hypnosis sessions
Evolution of anxiety between D0 and W6 according to the gender of the patient
Time frame: Week 6 after 2 hypnosis sessions
Evolution of anxiety between D0 and M3 according to the gender of the patient
Time frame: Month 3 after 3 hypnosis sessions
Evolution of anxiety between D0 and W6 according to age category
Time frame: Week 6 after 2 hypnosis sessions
Evolution of anxiety between D0 and M3 according to age category
Time frame: Month 3 after 3 hypnosis sessions
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Hematologic Cancer
Recruiting
HEME Home Transfusion Program
Leukemia, Myeloma
Active, not recruitingObservational study
Observatory of Prolymphocytic Leukemia T
Prolymphocytic Leukemia, T-cell Leukemia
RecruitingPhase 2
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
RecruitingPhase 2
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
RecruitingPhase 1
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
B-All, Acute Lymphoblastic Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Thomas BERT principal investigator
Hospices Civils de Lyon
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing anxiety questionnaire in people with Hematologic Cancer, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Thomas BERT (04.78.86.43.45, thomas.bert01@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evolution of anxiety (time frame: Week 6 after 2 hypnosis sessions). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.